Bray Named to Cortexyme Board of Directors
13 June 2022 - - US-based clinical-stage biopharmaceutical company Cortexyme, Inc. (NASDAQ: CRTX) has appointed June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company's board of directors, the company said.

To the Cortexyme board of directors, Bray brings more than forty years of extensive US and global regulatory experience in the healthcare industry and a proven track record of successful regulatory interactions with health authorities which have led to the approval of 32 NDAs in the US and multiple international approvals.

She most recently served as senior vice president, Global Regulatory Affairs and Medical Writing at Allergan, where she was responsible for regulatory strategies on development projects and lifecycle management in all therapeutic areas, including psychiatry and neurology.

During her tenure, she led numerous NDA approvals, including Namenda XR, Namzaric, Vraylar, and Ubrelvy.

Previously, Bray served as vice president, Regulatory Affairs at Organon (now Merck), where she led regulatory activities for development and marketed products, including the NDA for Saprhis (asenapine) for the treatment of schizophrenia and bipolar disorder.

Earlier in her career, Bray held numerous roles of increasing responsibility over a 25-year period at Berlex Laboratories, Inc. (now Bayer HealthCare Pharmaceuticals).

She began her pharmaceutical career in sterile manufacturing at Hoechst-Roussel Pharmaceuticals (now Sanofi-Aventis). Bray holds a B.S. in Pharmacy from the University of Rhode Island and an M.B.A in Pharmaceutical Marketing from Fairleigh Dickinson University.

Cortexyme, Inc. (NASDAQ: CRTX) is a clinical stage biopharmaceutical company focused on rare and degenerative diseases.

The company's innovative pipeline includes a precision bone growth molecule and drug-targeting platform to treat rare skeletal diseases, bone cancer and injury, in addition to small molecule therapeutics targeting the infectious pathogen P. gingivalis' role in degenerative disease progression, including for indications such as periodontal disease, oral potentially malignant disorders, and Alzheimer's disease, among others.